Admission Date:  [**2167-7-16**]              Discharge Date:   [**2167-7-23**]  Date of Birth:  [**2090-9-8**]             Sex:   F  Service: MEDICINE  Allergies: Lasix / Persantine I.V.
/ Theophylline / Nystatin  Attending:[**First Name3 (LF) 425**] Chief Complaint: Chest pain, shortness of breath  Major Surgical or Invasive Procedure: s/p Cardiac Catheterization (stable CAD, no intervention)   History of Present Illness: 76 year old female with history of CAD status post CABG in [**2145**] (SVG-LAD/D1), CHF (EF 30%), DM2, [**Hospital 109679**] transferred from [**Hospital1 56809**] for consideration of cardiac cath.
She describes associated chest pain over her left precordium without radiation, as well as bilateral shoulder pain, abdominal pain, and back pain.
She was given an additional dose of 0.5 mg IV bumetanide and admitted to telemetry for cycling of cardiac enzymes.
On the night of [**7-15**], however, her shortness of breath was severe enough to require ICU transfer for BIPAP initiation.
She was started on heparin and integrillin drips at this point secondary to concern for ischemia, with troponin peaking at 1.5, with normal CKs.
Of note, about 1 month ago her cardiologist (Dr. [**Last Name (STitle) **] cut her bumetanide dose in half secondary to rising creatinine, and her aldactone was discontinued completely secondary to hyperkalemia.
Past Medical History: 1)CAD: [**2145**]: CATH/PTCA: Patient underwent PTCA which was complicatd by abrupt closure requiring CABG (SVG->LAD/D1).
Subsequently, patient underwent relook procedure and found to have patent DCA site.
2) CHF:  Last echo [**4-17**] with resting regional wall motion abnormalities including septal, anterior and mid and apical lateral and apical inferolateral severe hypokinesis to akinesis, EF 30%.
Treated with modified radical mastectomy with skin graft; Tamoxifen x 7 yrs; arimidex x 1.5 yrs, then taxotere, now exemestane since [**1-19**].
9) Status post cholecystectomy [**70**]) Pulmonary nodule   Social History: Denies any smoking history, occasional alcohol, no IVDU.
Pertinent Results: Labs:  [**2167-7-20**]  WBC-3.9 RBC-3.60 Hgb-10.2 Hct-29.1 MCV-81 MCH-28.4           MCH 35.1 RDW-17.2 Plt Ct-100 [**2167-7-19**]  PT-13.4 PTT-73.5 INR(PT)-1.2 [**2167-7-20**]  Glucose-179 UreaN-34 Creat-1.7 Na-135 K-4.1 Cl-95 HCO3-27 [**2167-7-16**]  Glucose-156 UreaN-26 Creat-1.5 Na-141 K-3.9 Cl-101 HCO3-29           AnGap-15 [**2167-7-16**]  ALT-42 AST-29 CK(CPK)-115 AlkPhos-35 TotBili-1.2 [**2167-7-17**]  CK-MB-5 cTropnT-0.08 [**2167-7-20**]  Calcium-8.9 Phos-3.2 Mg-2.0 [**2167-7-18**]  URINE RBC->1000* WBC-124* Bacteri-NONE Yeast-NONE Epi-0 [**2167-7-18**]  URINE Blood-LGE Nitrite-NEG Protein-500 Glucose-NEG Ketone-TR           Bilirub-NEG Urobiln-NEG pH-5.0 Leuks-MOD [**2167-7-18**]  URINE Color-Yellow Appear-Cloudy Sp [**Last Name (un) **]-1.015 [**2167-7-22**]  URINE CULTURE Final:    NO GROWTH.
4.The aortic valve leaflets (3) are mildly thickened.
Unchanged sclerotic lesions in bone and prior radiation in right lung apex.
Brief Hospital Course: 76 year old female with history of CAD status post CABG in [**2145**] (SVG-LAD/D1), CHF (EF 30%), DM2, [**Hospital 109679**] transferred from [**Hospital1 56809**] for consideration of cardiac cath in the setting of recurrent episodes of shortness of breath and chest pain, thought to be acute pulmonary edema.
After reviewing the prior cath films ([**6-17**]) with the attending, it was determined to send the patient for catherization on [**2167-7-20**].
She was managed medically with hypertension control with medication changes as follows:  Added Lisinopril 10mg.
On the night of her admission she had transient hypotension in response to morphine 2 mg IV that responded to narcan reversal.
Future IV narcotics should be given judiciously.
Cath showed no new lesions and no further intervention was recommended.
Patient was sent for stat chest xray, UA, Blood&urine cultures.
It was determined that given the UA and impending catherization to start empiric therapy with Ciprofloxacin 250mg [**Hospital1 **].
Initially, it was thought the febrile episode was due to the recent addition of Procrit and it was discontinued.
Immediately, 1gm of Vancomycin IV was started.
Patient given mucomyst for renal protection, as well as 1/2 NS in a.m prior to catherization.
Continued beta blockade with metoprolol.
On [**2167-7-17**], it was decided to discontinue hydralazine and start Lisinopril 5mg qd and Bumex 0.5mg [**Hospital1 **].
Other blood pressure meds were held.
After [**2167-7-19**], patient's blood pressure was stable on the following regimen: Metoprolol 12.5mg [**Hospital1 **], isorbide dinitrate 10mg tid, and Lisinopril 5mg qd.
Upon discharge, patient to be discontinued off metoprolol and started on Toprol XL 25mg and Lisinopril 10mg daily.
Patient started on heparin gtt sliding scale.
Due to elevated PTT (>150), heparin had been withheld.
However, it was determined that access (Port-A-Cath) contributed to falsley elevated PTT and access was established on dorsum of hand.
Heparin gtt immediately restarted according sliding scale protocol.
Upon discharge, will restart warfarin when able with Lovenox for anticoagulation until therapeutic INR.
On iron supplements and procrit.
Discussed this with hematology/oncology, who recommended continuing examestane.
Reglan was added to her bowel regimen and patient admitted to having a bowel movement.
Medications on Admission: 1) Glimepiride 8 mg PO DAILY 2) Valsartan 160 mg PO BID 3) Toprol XL 25 mg PO DAILY 4) Bumetanide 1 mg PO DAILY 5) Xanax 0.25 mg PO TID 6) Kcl 10 meq PO DAILY 7) ASA 81 mg PO DAILY 8) Isosorbide mononitrate 30 mg PO DAILY 9) Pantoprazole 40 mg PO DAILY 10) Exemestane 25 mg PO DAILY 11) Atorvastatin 10 mg PO DAILY 12) Sertraline 100 mg PO DAILY 13) Warfarin 5 mg PO QMWF, 2.5 mg PO QTTH 14) Colace 100 mg PO BID 15) Senna 2 tabs PO QHS 16) FeSO4 325 mg PO BID 17) Oxycontin 20 mg PO QAM, 50 mg PO QPM 18) Oxycodone 5-10 mg PO Q6 hours prn 19) NTG SL 0.3 mg prn   Discharge Medications: 1.
Alprazolam 0.25 mg Tablet Sig: One (1) Tablet PO TID (3 times a day).
Pantoprazole 40 mg Tablet, Delayed Release (E.C.)
Oxycodone 10 mg Tablet Sustained Release 12HR Sig: Two (2) Tablet Sustained Release 12HR PO QAM (once a day (in the morning)).
Lactulose 10 g/15 mL Syrup Sig: Thirty (30) ML PO BID (2 times a day).
Levobunolol 0.5 % Drops Sig: One (1) Drop Ophthalmic  [**Hospital1 **] (2 times a day).
Exemestane 25 mg Tablet Sig: One (1) Tablet PO qHS () as needed for breast cancer.
Warfarin 5 mg Tablet Sig: 1 tablet alternating with 1/2 tablet Tablet PO 5 mg QMWFSun, 2.5 mg QTThSat: RESUME YOUR PREVIOUS SCHEDULE/DOSING.
Ferrous Sulfate 325 (65) mg Tablet Sig: One (1) Tablet PO DAILY (Daily).
Atorvastatin 10 mg Tablet Sig: One (1) Tablet PO once a day.
Aspirin 81 mg Tablet Sig: One (1) Tablet PO once a day.
Lisinopril 10 mg Tablet Sig: One (1) Tablet PO once a day.
Toprol XL 25 mg Tablet Sustained Release 24HR Sig: One (1) Tablet Sustained Release 24HR PO once a day.
Reglan 5 mg Tablet Sig: One (1) Tablet PO qACHS.
Isosorbide Mononitrate 30 mg Tablet Sustained Release 24HR Sig: One (1) Tablet Sustained Release 24HR PO DAILY (Daily).
Lovenox 60 mg/0.6 mL Syringe Sig: One (1) injection Subcutaneous twice a day for 10 days.
Oxycodone 40 mg Tablet Sustained Release 12HR Sig: One (1) Tablet Sustained Release 12HR PO QPM (once a day (in the evening)).
Oxycodone 10 mg Tablet Sustained Release 12HR Sig: One (1) Tablet Sustained Release 12HR PO qPM.
Amaryl 4 mg Tablet Sig: Two (2) Tablet PO once a day.
Please take all medications as prescribed.
We have made a number of medication changes as follows: 1) Please stop taking your valsartan.
We have replaced this medication with lisinopril 10 mg once a day.
2) We have started you on a new medication called Reglan (metoclopramide) to help you digest your food and hopefully help decrease your stomach and chest pains.
You should take this medication just prior to meals, and at night before bed.
3) Please take only 81 mg of aspirin daily since you are also on coumadin and don't want to keep your blood too thin.
4) You will be on lovenox injections until your INR is at goal of [**1-16**].
